AstraZeneca PLC Stock Performance
AstraZeneca PLC shares have experienced notable short-term weakness despite strong longer-term gains. Per SID market data, AZN trades at $158.61 with a one-month decline of 5.0% and a steeper three-month pullback of 18.95%, indicating sustained selling pressure. However, the stock has delivered an impressive 85.55% return over the trailing twelve months, reflecting significant long-term appreciation. Technically, AZN is trading below both its 50-day moving average of $163.08 and its 200-day moving average of $167.54, confirming a bearish near-term trend structure. The 14-day relative strength index stands at 39.4, approaching oversold territory but not yet triggering a classic oversold signal below 30. According to Massive/Polygon data, average daily trading volume is approximately 5.47 million shares. The stock's beta of 0.168 reflects extremely low correlation to broader market movements, consistent with its defensive healthcare sector positioning and large-cap market capitalization of approximately $280 billion.
AstraZeneca PLC Valuation Analysis
AstraZeneca PLC currently trades at a price-to-earnings ratio of 33.06, representing a premium valuation relative to the broader healthcare sector, per SID market data. The PEG ratio stands at 4.53, suggesting the stock's earnings growth rate does not proportionally justify its elevated P/E multiple at current levels. According to SEC filings, the price-to-book ratio is 6.24, indicating the market prices AZN at more than six times its book value, a level common among large pharmaceutical companies with substantial intangible asset portfolios. The company offers a dividend yield of approximately 1.56%, providing modest income to shareholders. With a market capitalization of roughly $280 billion, AstraZeneca remains one of the largest pharmaceutical companies globally. The combination of a high P/E, elevated PEG ratio, and premium price-to-book suggests the market continues to price in expectations of robust pipeline-driven revenue growth despite the recent stock price correction.
Smart Money Activity for AZN
AstraZeneca PLC carries an overall smart money score of 59 out of 100 with a neutral signal, per SID market data. The institutional component stands at a perfect 25 out of 25, indicating maximum institutional ownership conviction and broad participation from large asset managers. In contrast, the dark pool activity score registers at just 9.1 out of 25, suggesting relatively limited off-exchange block trading activity in recent periods. According to SEC Form 4 filings, insider activity has been modestly positive, with two insider transactions recorded over the past 90 days — both purchases and zero sales. The insider score sits at 12.5 out of 25, reflecting a neutral-to-slightly-positive insider sentiment. Congressional trading activity scores 12 out of 25, indicating no significant directional bias from disclosed congressional transactions. The divergence between maximum institutional confidence and subdued dark pool activity creates a mixed composite reading, consistent with the overall neutral smart money signal assigned to the stock.
AstraZeneca PLC Earnings Outlook
AstraZeneca PLC has delivered consecutive earnings beats in its two most recently reported quarters. According to company earnings reports, the quarter reported on April 29, 2026 posted actual earnings per share of $2.58 against an estimate of $1.53, representing a positive surprise of $1.05, or approximately 68.6%. The subsequent quarter reported on July 27, 2026 showed further acceleration, with actual EPS of $2.63 versus the $1.52 consensus estimate, yielding a surprise of $1.11, or roughly 73.0%. These substantial beats indicate AstraZeneca's operational performance has significantly exceeded analyst expectations. Looking ahead, per analyst estimates, the upcoming quarter on July 28, 2026 carries a consensus estimate of $1.44 per share, while the following quarter on November 5, 2026 has an estimate of $1.35. The declining estimate trajectory for future quarters contrasts with the pattern of outsized recent beats, creating uncertainty around forward earnings expectations.
Wall Street Analyst Ratings for AZN
Wall Street analyst sentiment on AstraZeneca PLC remains divided, with recent coverage reflecting a clear split between bullish and bearish viewpoints. According to Wall Street analyst reports, Berenberg Bank reiterated a Buy rating on July 13, 2026, representing the most recent coverage action. Jefferies has maintained a consistently bullish stance, reiterating Buy ratings on both June 9 and June 26, 2026, underscoring sustained conviction in the company's growth trajectory. Conversely, Deutsche Bank has taken a bearish position, issuing Sell ratings on both June 11 and June 26, 2026, making it a notable outlier among major firms covering the stock. Per SID consensus data, the five most recent analyst actions consist of three Buy ratings and two Sell ratings, with no Hold ratings represented, highlighting a polarized view. The absence of moderate positions suggests analysts hold strong directional convictions about AstraZeneca's pipeline prospects, regulatory outlook, and competitive positioning within the global pharmaceutical landscape.
